BRAFi/MEKi as second-line therapy provides higher ORR, as in a large retrospective analysis, metastatic melanoma patients resistant to PD-1 who were treated with PD-1 + CTLA4 achieved an ORR of 31%, while among those treated with CTLA4 monotherapy only 12% [19]. The gene discussed is CTLA4; the disease is metastatic melanoma.